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Abstract: Present study was aimed to identify most frequent mutations in rpoB gene region and to evaluate the 
association between mutations in rpoB gene and resistance levels to Rifampicin in clinical isolates of 
Mycobacterium tuberculosis of different geographical regions of India. A total of 100 clinical isolates of 
Mycobacterium tuberculosis were included in this study. Drug susceptibility testing against first line anti-
tuberculosis drugs was performed on LJ medium by conventional minimal inhibitory concentration (MIC) method 
and the mutation(s) in rpoB gene of M. tuberculosis isolates were analyzed by sequencing method. Of the 100 M. 
tuberculosis isolates, 31 (31.0%) and 18 (18.0%) were found resistant and susceptible for all four first-line anti-
tuberculosis drugs. The genetic mutations were observed in 96% (72/75) rifampicin-resistant M. tuberculosis 
isolates, while 4% (3/75) of rifampicin-resistant isolates did not have any mutation in rpoB gene. The mutation 
TCG531TTG (Ser531Leu) was found as most common and frequent mutation in 69.3% (52/75) of rifampicin-
resistant isolates of M. tuberculosis with MIC level (≥ 512mg/l). The mutation at codon 511 was associated with 
low degree (128mg/l) of rifampicin-resistance, deletions at codons 514-516 or substitution at codon 516 were 
found to be associated with moderate degree (256mg/l) of rifampicin-resistance and mutations at codon 526, 531 
were associated with the high degree (512mg/l) of rifampicin-resistance in M. tuberculosis isolates of Indian 
origin. The findings of this study will be useful for the development of raid and more specific indigenous 
molecular tools for the early diagnosis of multidrug-resistant tuberculosis in the country.   
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1. Introduction 
 
Tuberculosis (TB) caused by Mycobacterium 
tuberculosis (M. tuberculosis) is the leading cause of 
death in the world from a preventable and curable 
infectious disease. It has been estimated that there were 
9.6 million new TB cases (5.4 million men, 3.2 million 
women, and 1.0 million children) and 1.5 million TB 
deaths (890 000 men, 480 000 women, and 140 000 
children) in 2014, worldwide [1]. India has the highest 
burden of TB cases and accounted for 27% of global 
TB notifications in 2014 [1]. In recent years, the rise of 
multidrug-resistant tuberculosis (MDR-TB; resistance 
to both isoniazid and rifampicin with or without for 
other drugs) is the major hurdle for the control and 
effective management of TB worldwide. The case of 
MDR-TB is difficult to cure and requires prolonged 
treatment with expensive and often toxic multidrug 
regimens. 
Rifampicin (RIF) is an important first-line anti-TB 
drug which shows bactericidal action against 
Mycobacterium tuberculosis. Resistance to RIF is very 
vital and is considered as a surrogate marker of MDR-
TB, as about 90% of rifampicin-resistant isolates were 
also found resistant to isoniazid (INH) drug [2,3]. RIF 
target β-subunit of bacterial RNA polymerase, encoded 
by rpoB gene and inhibits the early steps of translation 
of M. tuberculosis. Mutations in 81bp rifampicin-
resistance-determining (RRD) region of the rpoB gene 
have been reported in 94-96% rifampicin-resistant      
M. tuberculosis isolates [4-6]. 
In the current scenario, diagnosis of active TB and 
MDR strains are essential to interrupt the transmission 
and initiation of effective treatment and therefore better 
TB control in the community. Detection of                  
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M. tuberculosis using conventional solid culture and 
drug susceptibility testing (DST) is considered as the 
‘gold standard’ method of MDR-TB diagnosis. 
However, conventional methods for diagnosing MDR-
TB are expensive, labour intensive and time-consuming 
[4]. Hence, efforts have been made to develop rapid 
molecular assays for early detection of rifampicin-
resistance. These assays rely on the information 
available for the rpoB gene mutations from different 
settings. Previous studies have reported that the 
prevalence of individual mutations in M. tuberculosis 
differs geographically and may affect the 
sensitivity/specificity of molecular test [7-9]. Therefore, 
deeper understanding on the most frequent or novel 
mutations and their correlations with phenotypic drug 
susceptibility profile of clinical isolates is necessary for 
the development and/or implementation of molecular 
assay as routine diagnostics tests, in particular, 
geographical region. The present study reported the 
frequency and distribution of mutations in RRD region 
of rpoB gene and highlights the association of rpoB 
mutations with the level of resistance to RIF in clinical 
M. tuberculosis isolates of Indian origin. 
 
2. Materials and Methods 
 
2.1 Culture isolates and drug susceptibility testing 
A panel of 100 M. tuberculosis isolates, recovered 
from suspected MDR cases of pulmonary TB and 
H37Rv (TMC02) strain were obtained from the 
National Mycobacterial Repository Centre of our 
Institute for this study. The clinical isolates of             
M. tuberculosis belonged to Agra, Jaipur, New Delhi, 
Cochin, Port Blair and Haridwar region. All the isolates 
were screened for the susceptible / resistance pattern to 
RIF (64mg/l), INH, Ethambutol (EMB) and 
Streptomycin (SM) drugs using conventional minimal 
inhibitory concentration (MIC) method as described by 
Das et al., [10]. MIC was determined using standard 
criteria of counting the colony-forming units (CFUs) 
and comparing with susceptible reference strain M. 
tuberculosis H37Rv [11, 12]. Isolates found resistant to 
RIF (64mg/l) were further tested at 128, 256, 512mg/l 
in order to determine their level to resistance MIC 
values. 
 
2.2 DNA isolation and PCR sequencing of the rpoB 
gene 
DNA was extracted from all isolates of                 
M. tuberculosis using lysozyme and proteinase-K 
treatment as per van Embden et al., [13]. A 350bp 
region of rpoB locus was amplified using the PCR 
primers: forward, 5’- GGGAGCGGATGACCACCC -
3’ and reverse 5’- GCG 
GTACGGCGTTTCGATGAAC -3’. Briefly, PCR  were 
set up in volume of 50l, using  200ng of genomic 
DNA, 1X reaction buffer (50mM KCl, Tris-HCl, pH-
9.0), 0.2mM each of dNTPs, 1.5mM MgCl2, and 1 unit 
Taq DNA polymerase. The reaction mixture was 
performed in a ‘GeneAmp PCR System 9700’ thermal 
cycler (Applied Biosystems, USA). Thermal cycling 
was as follows: initial denaturation at 940C for 4 min., 
followed by 35 cycles of denaturation at 940C for 1 
min., annealing at 600C for 1 min., extension at 720C 
for 2 min., and final extension at 720C for 10 min. 
Amplicon sizes of 350bp were considered positive in 
amplification of PCR, after separation on 2% agarose 
gel for 1.30 hrs at 50 volts (3.8V/Cm2). 
 
2.3 DNA sequencing and In-silico analysis 
Amplicon of rpoB gene was resolved on 1% 
agarose gel and band of 350bp was excised. DNA was 
extracted from the gel slices using QIAEX II Gel 
Extraction kit (QIAGEN, USA). Each sequencing 
reaction of 20µl volume consisted of 200ng genomic 
DNA, 3.5pmol of forwarding primer, 8µl sequencing 
mix (BigDye Terminator Cycle Sequencing Kit v3.1, 
Applied Biosystems) and adjusted to a final volume of 
20l by adding distilled water. The cycling parameters 
were as follows: 30 cycles of 96°C for 30 Sec and 60°C 
for 4 min. Amplicon was purified by adding 0.1 volume 
of  3M sodium acetate (pH 4.5) and 2.5 volume of 
absolute ethanol. The sequencing of the amplicon was 
carried out using the ABI PRISM 310 DNA sequencer 
(Applied Biosystems, USA). The generated sequences 
were compared with wild type rpoB gene sequence of 
M. tuberculosis H37Rv using MegAlign program of 
DNASTAR software (Madison, WI, USA). 
 
3. Results 
 
3.1 Drug-susceptible pattern of M. tuberculosis 
isolates 
Of the 100 M. tuberculosis isolates, 31 (31.0%) and 
18 (18.0%) were found resistant and susceptible for all 
four drugs (Table 1). Individually, 75 (75.0%), 79 
(79.0%), 45 (45%), 47 (47.0%) and 25 (25.0%), 21 
(21.0%), 55 (55.0%), 53 (53.0%), 75 (75%) isolates 
were resistant and susceptible to RIF, INH, EMB and 
SM, respectively. Of the 75 RIF-resistant isolates, 100, 
60 and 55.8% isolates were also resistant to INH, EMB, 
and SM, respectively. Detail results of drug 
susceptibility pattern of tuberculosis isolates are 
summarized in Table 1. 
 
Table 1. Drug susceptibility profiles of M. tuberculosis isolates. 
 
Drug susceptibility profile 
No. of isolates 
RIF INH EMB SM 
S S S S 18 
S R S S 4 
S S S R 3 
R R S S 17 
R R R S 14 
R R S R 13 
R R R R 31 
Total 100 
S: Sensitive; R: Resistant 
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3.2 Mutations in rpoB gene of M. tuberculosis and 
their association with RIF resistance levels 
Out of 75 rifampicin-resistant isolates, 72 (96%) 
isolates were found to have mutations at different 
codons of rpoB gene region. Whereas remaining 3 (4%) 
RIF-resistant isolates and all RIF sensitive isolates 
(n=25) did not have any mutation in targeted region.  
The following mutations in rpoB gene region were 
observed in RIF-resistant isolates:  CTC511CCG 
(Leu511Pro) in 2.6% (2/75) isolates with MIC level ≤ 
128 mg/l; deletions  514 –TC, 515-ATG (Met) and 516- 
G. in one RIF-resistant isolate (1/75, 1.3%) with MIC 
level ≤ 256mg/l of RIF-resistant. The mutation 
CAC516GTC (Asp516Val) was found in 6 (8%) RIF-
resistant isolates with MIC level ≤ 256mg/l. Mutations 
were found as CAC526CGC (His526Arg) in 1.3% 
(1/75) isolate, CAC526TAC (His526Tyr) in 8% (6/75) 
isolates, and CAC526AAC (His526Asn) in 2.6% (2/75) 
isolates, all of them exhibiting MIC level ≤ 512mg/l. 
The mutation TCG531TGG (Ser531Trp) was exhibited 
in 2.6% (2/75) of RIF-resistant isolates and the most 
common and frequent mutation of TCG531TTG 
(Ser531Leu) was observed in 69.3% (52/75) RIF-
resistant isolates with MIC level (≥ 512mg/l) (Table 2). 
 
Table 2.  Results of correlation between MICs of Rifampicin and mutations in the rpoB gene of M. tuberculosis isolates. 
 
Sequence/ amino acid alteration RIF MIC RIF + INH RIF + INH + EMB RIF + INH + SM RIF + INH + EMB No. Isolates (%) 
CTC511CCG (Leu511Pro) ≤ r64 1 0 1 0 2(2.6) 
Deletions 514 –TC; 515-ATG (Met); 516-G ≤ r64 1 0 0 0 1(1.3) 
CAC516GTC (Asp516Val) ≤ r128 3 1 1 1 6(8) 
CAC526CGC (His526Arg) ≤ r256 0 0 1 0 1(1.3) 
CAC526TAC (His526Tyr) ≤ r512 4 1 0 1 6(8) 
CAC526AAC (His526Asn) ≤ r512 0 1 0 1 2(2.6) 
TCG531TTG (Ser531Leu) ≥ r512 6 10 9 27 52(69.3) 
TCG531TGG (Ser531Trp) ≤ r512 0 1 0 1 2(2.6) 
Wild type ≤ r64 2 0 1 0 3(4) 
Total  17 14 13 31 75 
R-rifampicin; H-isoniazid; E-ethambutol; SM-streptomycin; r-resistant 
 
4. Discussion 
 
Multidrug-resistant tuberculosis has been emerged 
as a global problem, with high incidence in low-income 
countries including India. The diagnosis of drug-
resistant isolates depends on conventional methods, 
which required long (4-5 weeks) incubation period. 
Molecular methods have shown the promises for rapid 
detection of MDR. However, the sensitivity and 
specificity of these methods depend on the genetic 
diversity of isolates [14]. These problems can be 
overcome by DNA sequencing of the core region of the 
rpoB gene. Present study employed DNA sequencing as 
‘gold standard’ test for the detection of genetic 
mutations in RDR region of rpoB gene of clinical 
isolates of M. tuberculosis. Previous studies have also 
used DNA sequencing method for the study of genetic 
mutation and genetic diversity of M. tuberculosis 
isolates in different settings [15-17]. 
In present study, a total of 100 clinical isolates of 
M. tuberculosis were subjected to drug susceptibility 
testing and 75 (75.0%) were found resistant to RIF 
using MIC method. All the RIF-resistant isolate were 
found to be resistant to INH (Table 1). These findings 
support the previous studies and further confirmed that 
RIF is a surrogate marker for the multidrug-resistance 
in TB [18,19]. Similarly, most of the EMB-resistant 
isolates were INH-resistant, suggesting a high degree of 
association between EMB and INH-resistance. Present 
findings supported our previous study which reported 
85.18% EMB-resistant isolates were resistant to INH 
[20]. Madison et al., [21] have also reported that EMB-
resistance was accompanied by 96.6 percent resistance 
to INH. This association was not merely a matter of 
chance as the same trend of EMB-resistance with INH-
resistance has also been previously observed in north 
Indian cities (Agra, Delhi, Jaipur, and Varanasi) by 
Gupta et al., [20]. 
In the present study, DNA sequencing was 
employed for the detection of mutations in RRD region 
of the rpoB gene and mutations were observed in rpoB 
locus in 96% (72/75) of RIF-resistant isolates. The 
frequency of the rpoB gene mutations observed in the 
present study is within the previously reported range of 
95-96% [18,22]. In the present study, of 75 RIF- 
resistant isolates, 3 (4%) isolates did not have any 
mutation in the targeted region. Previously, other 
researchers were also not reported any mutations in 
rpoB region of few RIF-resistant isolates [16,23]. These 
findings indicated that in these isolates alternate 
mechanisms of drug-resistance (such as efflux pump) 
might be responsible for RIF-resistant phenotype of the 
isolates [24]. 
In the present study, we have observed Leu511Pro, 
Asp516Val, His526Arg, His526Tyr, His526Asn, 
Ser531Leu, and Ser531Trp substitution mutations in 
RIF-resistant isolates. Previous studies have also 
reported these common mutations in RIF isolates of 
different geographical regions [18,22,25,26]. In present 
study, 1 RIF-resistant isolate (1/75, 1.3%) had deletions 
(514 –TC, 515 –ATG, 516 –G) and correlate with MIC 
level ≤ 256mg/l. Previously, an isolated study has also 
reported deletions - 514 TTC (Phe), 515 ATG (Met) 
and 516 GAC (Asp) in 1 (1.2%) RIF-resistant isolate 
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[27]. The mutations Asp516Val in 8% (6/75) isolates 
with MIC ≤ 256mg/l, His526Arg in 1.3% (1/75), 
His526Asn in 1.3% (1/75), His526Tyr in 8% (6/75) 
isolates were observed with MIC ≤ 512mg/l in present 
study. These mutations have also been reported by 
others researchers- Asp516Val in 1.8-6.2% and 
His526Arg/ Asn /Tyr in 0.6-11% of RIF-resistant 
isolates [16,26,28]. In our study, the most common 
mutation, Ser531Leu, was found in 69.3% (52/75) 
isolates with MIC ≥ 512mg/l and Ser531Trp in 1.3% 
(1/75) with MIC ≤ 512mg/l. The frequencies of these 
mutations reported by other workers were: Ser531Leu 
in 46.3 - 71% of RIF-resistant isolates and Ser531Trp in 
1.2-16.5% of RIF-resistant isolates [14,28]. 
In present study, strong correlation was found 
between mutation at specific codon and degree of 
resistance to RIF; mutation at codon 511 is associated 
with low degree (128mg/l) of RIF-resistance, deletions 
at codons 514-516 or substitution at codon 516 are 
associated with moderate degree (256mg/l) of RIF-
resistance and mutations at codon 526, 531 are 
associated with the high degree (512mg/l) of RIF 
resistance in M. tuberculosis isolates of study settings. 
Similar to the present study, Bobadilla-del-Valle et al., 
[29] also reported the point mutations in codon 513, 526 
and 531 was associated with the high degree of 
resistance to RIF, whereas mutations in codon 516 were 
observed in low-level RIF-resistance in isolates of      
M. tuberculosis. Other researchers also reported an 
association between high and low level of resistance to 
RIF and of specific mutations in RRDR region of       
M. tuberculosis [30-32]. In conclusion, the findings of 
this study will be useful for the surveillance of 
geographical and temporal trends in the prevalence of 
specific mutations, as well as for research on the 
implications of geographical differences in mutation 
frequencies for the development of indigenous 
diagnostic tools for drug-resistant TB in the country. 
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